Review of the treatment of non-small cell lung cancer with gefitinib

Takuya Araki, Hideaki Yashima, Kimihiro Shimizu, Tohru Aomori, Tadahiro Hashita, Kyoichi Kaira, Tomonori Nakamura, Koujirou Yamamoto

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.

Original languageEnglish
Pages (from-to)407-421
Number of pages15
JournalClinical Medicine Insights: Oncology
Volume6
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Therapeutics
Protein-Tyrosine Kinases
Japan
gefitinib
Mutation
Neoplasms

Keywords

  • EGFR
  • Gefitinib
  • KRAS
  • Lung cancer
  • NSCLC

ASJC Scopus subject areas

  • Oncology

Cite this

Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., ... Yamamoto, K. (2012). Review of the treatment of non-small cell lung cancer with gefitinib. Clinical Medicine Insights: Oncology, 6, 407-421. https://doi.org/10.4137/CMO.S7340

Review of the treatment of non-small cell lung cancer with gefitinib. / Araki, Takuya; Yashima, Hideaki; Shimizu, Kimihiro; Aomori, Tohru; Hashita, Tadahiro; Kaira, Kyoichi; Nakamura, Tomonori; Yamamoto, Koujirou.

In: Clinical Medicine Insights: Oncology, Vol. 6, 2012, p. 407-421.

Research output: Contribution to journalArticle

Araki, Takuya ; Yashima, Hideaki ; Shimizu, Kimihiro ; Aomori, Tohru ; Hashita, Tadahiro ; Kaira, Kyoichi ; Nakamura, Tomonori ; Yamamoto, Koujirou. / Review of the treatment of non-small cell lung cancer with gefitinib. In: Clinical Medicine Insights: Oncology. 2012 ; Vol. 6. pp. 407-421.
@article{2cb3c21da783475daf90687655497227,
title = "Review of the treatment of non-small cell lung cancer with gefitinib",
abstract = "In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80{\%} of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.",
keywords = "EGFR, Gefitinib, KRAS, Lung cancer, NSCLC",
author = "Takuya Araki and Hideaki Yashima and Kimihiro Shimizu and Tohru Aomori and Tadahiro Hashita and Kyoichi Kaira and Tomonori Nakamura and Koujirou Yamamoto",
year = "2012",
doi = "10.4137/CMO.S7340",
language = "English",
volume = "6",
pages = "407--421",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Review of the treatment of non-small cell lung cancer with gefitinib

AU - Araki, Takuya

AU - Yashima, Hideaki

AU - Shimizu, Kimihiro

AU - Aomori, Tohru

AU - Hashita, Tadahiro

AU - Kaira, Kyoichi

AU - Nakamura, Tomonori

AU - Yamamoto, Koujirou

PY - 2012

Y1 - 2012

N2 - In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.

AB - In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.

KW - EGFR

KW - Gefitinib

KW - KRAS

KW - Lung cancer

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84870933405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870933405&partnerID=8YFLogxK

U2 - 10.4137/CMO.S7340

DO - 10.4137/CMO.S7340

M3 - Article

C2 - 23239933

AN - SCOPUS:84870933405

VL - 6

SP - 407

EP - 421

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -